Tempest Therapeutics
TPSTTempest Therapeutics is pioneering the development of small molecule therapies that target the tumor microenvironment to overcome resistance and enhance anti-tumor immune responses. Its lead candidates are designed to inhibit immunosuppressive pathways, such as those driven by PPARα and prostaglandin receptors, with the goal of creating more effective treatments for advanced solid tumors. The company has advanced multiple programs into clinical development and is exploring strategic partnerships to maximize the potential of its pipeline. Tempest's approach aims to address significant unmet needs in oncology by combining its novel agents with established immunotherapies.
TPST · Stock Price
Historical price data
AI Company Overview
Tempest Therapeutics is pioneering the development of small molecule therapies that target the tumor microenvironment to overcome resistance and enhance anti-tumor immune responses. Its lead candidates are designed to inhibit immunosuppressive pathways, such as those driven by PPARα and prostaglandin receptors, with the goal of creating more effective treatments for advanced solid tumors. The company has advanced multiple programs into clinical development and is exploring strategic partnerships to maximize the potential of its pipeline. Tempest's approach aims to address significant unmet needs in oncology by combining its novel agents with established immunotherapies.
Technology Platform
Focuses on developing small molecule therapeutics that modulate the tumor microenvironment by targeting specific immunosuppressive pathways, such as PPARα and prostaglandin E2 receptors (EP2/EP4), to enhance anti-tumor immunity.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Part 1 TPST-1120 + Part 2 TPST-1120 + nivolumab + Part 3 TPS... | Hepatocellular Carcinoma | Phase 1 | |
| TPST-1495 twice daily + TPST-1495 once daily or on intermitt... | Solid Tumor | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Faces competition from numerous biotechs targeting the tumor microenvironment, including developers of IDO inhibitors, A2AR antagonists, and other EP2/EP4 antagonists. Differentiation is based on the specificity of its small molecule designs and its focus on the PPARα pathway, where it may have a first-mover advantage in oncology.